Empagliflozin (JardianceĀ®), a potent, highly selective, sodium glucose cotransporter-2 (SGLT2) inhibitor, is an effective and generally well tolerated antihyperglycaemic agent approved for the treatment of adults with type 2 diabetes (T2D) in the EU, USA and Japan, among other parts of the world.
Sodium-glucose co-transporter-2 (SGLT2) inhibitors have several beneficial effects in patients with type 2 diabetes, including glucose lowering, weight loss, blood pressure lowering, and a reduced risk of major adverse cardiovascular events.
Boehringer Ingelheim and Eli Lilly and Company have announced that a New Drug Application (NDA) for the investigational sodium glucose...
MHLW (Japan) approved on February 9 Nippon Boehringer Ingelheimās SGLT2 inhibitor Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD)
The FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious...
The FDA has approved Synjardy (empagliflozin + metformin hydrochloride) tablets, from Boehringer Ingelheim and Eli Lilly, for the treatment of...
Objective: To examine whether lowering plasma glucose concentration with the sodium-glucose transporter-2 inhibitor empagliflozin improves β-cell function in patients with type 2 diabetes mellitus (T2DM).
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the resubmission of a New Drug Application (NDA) for the...
A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred...
The FDA has approved Glyxambi (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company as an adjunct...